<Header>
<FileStats>
    <FileName>20161028_10-K-A_edgar_data_1497130_0001663577-16-000356_2.txt</FileName>
    <GrossFileSize>70347</GrossFileSize>
    <NetFileSize>13601</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>47076</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>8</N_Tables>
    <N_Exhibits>3</N_Exhibits>
</FileStats>
<SEC-Header>
0001663577-16-000356.hdr.sgml : 20161028
<ACCEPTANCE-DATETIME>20161028151733
ACCESSION NUMBER:		0001663577-16-000356
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20120630
FILED AS OF DATE:		20161028
DATE AS OF CHANGE:		20161028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nano Mobile Healthcare, Inc.
		CENTRAL INDEX KEY:			0001497130
		STANDARD INDUSTRIAL CLASSIFICATION:	MEASURING & CONTROLLING DEVICES, NEC [3829]
		IRS NUMBER:				980659770
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55155
		FILM NUMBER:		161958310

	BUSINESS ADDRESS:	
		STREET 1:		3 COLUMBUS CIRCLE
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-520-4950

	MAIL ADDRESS:	
		STREET 1:		3 COLUMBUS CIRCLE
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vantage mHealthcare, Inc.
		DATE OF NAME CHANGE:	20150108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vantage Health
		DATE OF NAME CHANGE:	20100721

</SEC-Header>
</Header>

 0001663577-16-000356.txt : 20161028

10-K/A
 1
 mainbody.htm

UNITED
STATES  

  SECURITIES
AND EXCHANGE COMMISSION  

  WASHINGTON,
D.C. 20549  

FORM
10-K/A   

Amendment
No. 2   

Securities
                    registered under Section 12(b) of the Exchange Act:  

Title
    of each class  
      Name
    of each exchange on which registered   
 
        none    
        not
    applicable     

Securities
        registered under Section 12(g) of the Exchange Act:  

Common
    Stock, Par Value $0.001 per Share    

(Title
    of each class)   

Indicate
    by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   
 
        Yes   [  ]      No  [ X]    

Indicate
    by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   
 
        Yes   [  ]      No  [ X]    

Indicate
    by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
    Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
    reports), and (2) has been subject to such filing requirements for the past 90 days.   
 
        Yes   [X]      No  [   ]    

Indicate
    by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K ( 229.405 of this chapter) is
    not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information
    statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.   
 
        Yes   [X]      No  [   ]    

Indicate
    by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
    reporting company. See the definitions of  large accelerated filer,   accelerated filer  and  smaller
    reporting company  in Rule 12b-2 of the Exchange Act.   
 
      [    ]  

Accelerated
    filer  
      [    ]  

[    ]  

Smaller
    reporting company  
      [ X]   

Indicate
    by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   
 
        Yes   [  ]      No  [ X]    

State
    the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date.  80,025,000
    issued and outstanding as of September 30, 2012.   

DOCUMENTS
    INCORPORATED BY REFERENCE:   None.    

EXPLANATORY
NOTE   

Nano
Mobile Healthcare, Inc. (the  Company ) is filing this Amendment No.2 of Form 10-K/A (this  Amendment ) to
amend its Annual Report on Form 10-K for the year ended June 30, 2012 (the  Original Form 10-K ), originally filed with
the Securities and Exchange Commission on October 15, 2012, and later amended on October 19, 2012. The purpose of this Amendment
is solely to correct a typographical error which appeared on the cover page of the Original Form 10-K, and was reproduced in the
Company s amendment to the Original Form 10-K, which incorrectly identified the Company as a shell company. The Company
is making this Amendment to properly check the box that says  No,  the Company is not a shell company as defined in
Rule 12b-2 of the Exchange act.  

No
revisions are being made to the Company's financial statements. This Amendment speaks as of the original filing date, does not
reflect events occurring after the filing of the Original Form 10-K or subsequent amendment, or modify or update those disclosures
that may be affected by subsequent events, and no other changes are being made to any other disclosure contained in the Original
Form 10-K.     

PART
IV   

ITEM
15.  EXHIBITS, FINANCIAL STATEMENTS SCHEDULES   

(a)   
       Financial
    Statements and Schedules    

Financial
Statements (See Item 8)  

(b)   
       Exhibits    

SIGNATURES   

Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.  

Nano
Mobile Healthcare, Inc.  

By:  /s/
Joseph C. Peters   

  Joseph
C. Peters  

  President,
Chief Executive Officer, Principal Executive Officer,  

  Chief
Financial Officer, Principal Financial Officer,  

  Principal
Accounting Officer, and Director  

  October
28, 2016  

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.  

By:  /s/
Joseph C. Peters   

  Joseph
C. Peters  

  President,
Chief Executive Officer, Principal Executive Officer,  

  Chief
Financial Officer, Principal Financial Officer,  

  Principal
Accounting Officer, and Director  

  October
28, 2016  

By:  /s/
Tony van Bijleveld   

  Tony
van Bijleveld  

  Director  

  October
28, 2016  

By:  /s/
Dr. Steven R. Steinhubl   

  Steven
R. Steinhubl  

  Director  

  October
28, 2016  

<EX-31.1>
 2
 ex31_1.htm

CERTIFICATIONS  

I, Joseph C. Peters, certify that; 

1.  
       
      I have reviewed this annual report on Form 10-K/A for the year ended June 30, 2012 of Nano Mobile Healthcare, Inc. (the  registrant );   

2.  
       
      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   

3.  
       
      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;   

4.  
       
      The registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:   

a.  
       
      Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;   

b.  
       
      Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;   

c.  
       
      Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and   

d.  
       
      Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and   

5.  
       
      The registrant s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):   

a.  
       
      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and   

b.  
       
      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.   

Date: October 28, 2016 

/s/ Joseph C. Peters  

 By: Joseph C. Peters 

 Title: Chief Executive Officer 

</EX-31.1>

<EX-31.2>
 3
 ex31_2htm.htm

CERTIFICATIONS  

I, Joseph C. Peters, certify that; 

1.  
       
      I have reviewed this annual report on Form 10-K/A for the year ended June 30, 2012 of Nano Mobile Healthcare, Inc. (the  registrant );   

2.  
       
      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   

3.  
       
      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;   

4.  
       
      The registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:   

a.  
       
      Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;   

b.  
       
      Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;   

c.  
       
      Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and   

d.  
       
      Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and   

5.  
       
      The registrant s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):   

a.  
       
      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and   

b.  
       
      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.   

Date: October 28, 2016 

/s/ Joseph C. Peters  

 By: Joseph C. Peters 

 Title: Chief Financial Officer 

</EX-31.2>

<EX-32.1>
 4
 ex32_1.htm

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND   

  CHIEF FINANCIAL OFFICER  

  PURSUANT TO  

  18 U.S.C. SECTION 1350,  

  AS ADOPTED PURSUANT TO  

  SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002  

In connection with the annual Report of Nano
Mobile Healthcare, Inc. (the  Company ) on Form 10-K/A for the year ended June 30, 2012 filed with the Securities and
Exchange Commission (the  Report ), I, Joseph C. Peters, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 

1.              
  The Report fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934; and  

2.              
  The information contained in the Report fairly presents, in all material respects, the consolidated
financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods
presented.  

By:  
       /s/ Joseph C. Peters    
 
      Name:  
      Joseph C. Peters   
 
      Title:  
      Principal Executive Officer, Principal Financial Officer and Director   
 
      Date:  
      October 28, 2016   

This certification has been furnished solely pursuant to Section
906 of the Sarbanes-Oxley Act of 2002. 

</EX-32.1>

